#Sweden #Stockholm #2025 #Sobi #financial report

Sobi's Upcoming Financial Report

Sobi, a leading global biopharmaceutical company focused on rare diseases, has announced its upcoming financial report for the fourth quarter and the full year of 2025. This important document is scheduled for release on February 5, 2026, at 08:00 CET.

The publication will be an essential resource for investors, analysts, and media representatives eager to assess the company's financial performance and strategic direction. Following the release, Sobi will host a conference call at 13:00 CET, 12:00 GMT, and 07:00 EST where company leaders will present the results and engage in a question-and-answer session.

During the call, interested parties can follow the presentation live through Sobi’s website or access the materials later, as the presentation slides will be made available ahead of the call.

To join the conference call, participants need to dial in using specific numbers:

• - Sweden: +46 8 5051 0031
• - United Kingdom: +44 207 107 06 13
• - United States: +1 631 570 56 13

For those in other countries, dial-in details can be found on Sobi's official website.

Sobi is dedicated to advancing healthcare solutions that significantly improve the lives of those affected by rare diseases. With a workforce of approximately 1,900 employees across regions including Europe, North America, the Middle East, Asia, and Australia, Sobi has positioned itself as a crucial player in the biopharmaceutical arena. In 2024, the company reported impressive revenues totaling SEK 26 billion, a testament to its strong market performance and innovative capabilities.

The company's stock is publicly traded under the ticker STO SOBI on Nasdaq Stockholm, providing transparency and accessibility for investors. Sobi's growth trajectory and commitment to innovation make it a company to watch closely as it continues to enhance its portfolio with breakthrough therapies for patients with rare conditions.

For further inquiries or additional information about Sobi’s financial health and strategic trajectory, interested parties may contact the Investor Relations Team through the company's online resources. Media contacts are also available for those looking to engage with Sobi's communications team directly.

By planning the timely release of its financial results and facilitating a transparent, interactive platform for discussion, Sobi demonstrates its ongoing commitment to clarity and stakeholder engagement in the rapidly evolving landscape of biopharmaceuticals. Leaders in the industry will undoubtedly be paying attention to the insights and data shared in the upcoming report and call, as it will reflect the company’s adaptation and formulation of strategies in a challenging market.

Stay tuned for more updates as Sobi prepares to unveil its detailed financial insights for FY 2025, a year that promises to shape the pathways of treatment and support for those living with rare diseases.